MARKSANS PHARMA Financial Statement Analysis
|
||
|
The Revenues of MARKSANS PHARMA have increased by 8.33% YoY .
The Earnings Per Share (EPS) of MARKSANS PHARMA has increased by 30.38 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
MARKSANS PHARMA Last 5 Annual Financial Results
[BOM: 524404|NSE : MARKSANS]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹1,491 Cr | ₹1,376 Cr | ₹1,134,208,953 Cr | ₹1,000 Cr | ₹913 Cr |
| Expenses | ₹1,232 Cr | ₹1,037 Cr | ₹941,957,026 Cr | ₹868 Cr | ₹834 Cr |
| Operating Profit (Excl OI) | ₹259 Cr | ₹340 Cr | ₹192,251,927 Cr | ₹132 Cr | ₹78 Cr |
| Other Income | ₹42 Cr | ₹6.69 Cr | ₹327,767 Cr | ₹4.62 Cr | ₹8.47 Cr |
| Interest | ₹8.45 Cr | ₹7.99 Cr | ₹8,746,377 Cr | ₹9.66 Cr | ₹10 Cr |
| Depreciation | ₹45 Cr | ₹36 Cr | ₹26,661,549 Cr | ₹23 Cr | ₹27 Cr |
| Profit Before Tax | ₹248 Cr | ₹302 Cr | ₹157,171,768 Cr | ₹104 Cr | ₹50 Cr |
| Profit After Tax | ₹187 Cr | ₹239 Cr | ₹120,752,685 Cr | ₹80 Cr | ₹36 Cr |
| Consolidated Net Profit | ₹185 Cr | ₹236 Cr | ₹117,019,275 Cr | ₹76 Cr | ₹33 Cr |
| Earnings Per Share (Rs) | ₹5.88 | ₹4.51 | ₹5.76 | ₹2.86 | ₹1.87 |
| PAT Margin (%) | 13.01 | 12.06 | 17.14 | 10.65 | 8.04 |
| ROE(%) | 18.59 | 18.72 | 31.33 | 20.49 | 15.88 |
| ROCE(%) | 22.89 | 23.82 | 39.76 | 25.57 | 18.51 |
| Total Debt/Equity(x) | 0.02 | 0.04 | 0.02 | 0.03 | 0.18 |
Key Financials |
||
| Market Cap | : | ₹ 7,563.9 Cr |
| Revenue (TTM) | : | ₹ 2,103.4 Cr |
| Net Profit(TTM) | : | ₹ 320.0 Cr |
| EPS (TTM) | : | ₹ 7.1 |
| P/E (TTM) | : | 23.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MARKSANS PHARMA | -4.3% | 15.5% | 114.6% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
| CIPLA | 4.5% | -3.1% | 52.8% |
| DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
| ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
| DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
| MANKIND PHARMA | 2.7% | 12.4% | NA |
| TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
| LUPIN | 3.1% | -1.1% | 127.4% |
MARKSANS PHARMA Revenues
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | 8.33 % |
| 5 Yr CAGR | 13.05 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,491 Cr | 8.33 | |
| Mar2022 | ₹1,376 Cr | -100.00 | |
| Mar2021 | ₹1,134,208,953 Cr | 113,412,969.76 | |
| Mar2020 | ₹1,000 Cr | 9.57 | |
| Mar2019 | ₹913 Cr | - | |
MARKSANS PHARMA Operating Profit
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | -23.77 % |
| 5 Yr CAGR | 34.81 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹259 Cr | -23.77 | |
| Mar2022 | ₹340 Cr | -100.00 | |
| Mar2021 | ₹192,251,927 Cr | 145,485,485.38 | |
| Mar2020 | ₹132 Cr | 68.59 | |
| Mar2019 | ₹78 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -29.66 % |
| 5 Yr CAGR | 19.23 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 17.36% | -29.66 | |
| Mar2022 | 24.68% | 45.60 | |
| Mar2021 | 16.95% | 28.31 | |
| Mar2020 | 13.21% | 53.78 | |
| Mar2019 | 8.59% | - | |
MARKSANS PHARMA Profit After Tax
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | -21.77 % |
| 5 Yr CAGR | 53.85 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹185 Cr | -21.77 | |
| Mar2022 | ₹236 Cr | -100.00 | |
| Mar2021 | ₹117,019,275 Cr | 153,046,297.20 | |
| Mar2020 | ₹76 Cr | 132.12 | |
| Mar2019 | ₹33 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 7.88 % |
| 5 Yr CAGR | 12.79 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 13.01 % | 7.88 | |
| Mar2022 | 12.06 % | -29.64 | |
| Mar2021 | 17.14 % | 60.94 | |
| Mar2020 | 10.65 % | 32.46 | |
| Mar2019 | 8.04 % | - | |
MARKSANS PHARMA Earnings Per Share (EPS)
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | 30.38 % |
| 5 Yr CAGR | 33.16 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹5.88 | 30.38 | |
| Mar2022 | ₹4.51 | -21.70 | |
| Mar2021 | ₹5.76 | 101.40 | |
| Mar2020 | ₹2.86 | 52.94 | |
| Mar2019 | ₹1.87 | - | |
MARKSANS PHARMA Return on Capital Employed (ROCE)
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | -3.90 % |
| 5 Yr CAGR | 5.45 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 22.89% | -3.90 | |
| Mar2022 | 23.82% | -40.09 | |
| Mar2021 | 39.76% | 55.49 | |
| Mar2020 | 25.57% | 38.14 | |
| Mar2019 | 18.51% | - | |
MARKSANS PHARMA Share Price vs Sensex
| Current Share Price | : | ₹166.9 |
| Current MarketCap | : | ₹ 7,563.9 Cr |
| Updated EOD on | : | Apr 25,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MARKSANS PHARMA | -4.3% |
15.5% |
114.6% |
| SENSEX | 1.3% |
2.6% |
24% |
MARKSANS PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | 3.2% | 12.8% | 65.7% |
| S&P BSE MIDSMALLCAP | 2.4% | 10.7% | 64.9% |
| S&P BSE ALLCAP | 1.6% | 6% | 40.6% |
| S&P BSE HEALTHCARE | -0.2% | 3.7% | 52.1% |
No NSE index found
You may also like the below Video Courses
FAQ about MARKSANS PHARMA Financials
How the annual revenues of MARKSANS PHARMA have changed ?
The Revenues of MARKSANS PHARMA have increased by 8.33% YoY .
How the Earnings per Share (EPS) of MARKSANS PHARMA have changed?
The Earnings Per Share (EPS) of MARKSANS PHARMA has increased by 30.38 % YoY .
Check out Intrinsic Value of Peers of MARKSANS PHARMA
Compare Stock Analytics of Peers of MARKSANS PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
